Amarin Corp - רווח נקי למניה בארבעת הרבעונים האחרונים AMRN

This chart for Amarin Corporation plc (AMRN), which specializes in cardiology drugs, shows an EPS TTM of 78.30. The production of fish oil substances has been delegated to partners in Asia and Europe to ensure supply reliability. Margins are currently declining due to pressure from generics in the US, although foreign markets partially maintain patent protection. Management aims to reduce costs and expand its global footprint to stabilize finances.
AMRN (Amarin Corporation): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For the long-term investor, confirming profit sustainability amid Vascepa patent risks is key. This metric measures the dynamics of net earnings per share over a rolling year, neutralizing timing gaps between quarterly reports. Analyzing the relative EPS YoY TTM growth rate allows for an assessment of the real pace of the company's profitability recovery. In an environment of generic competition, this indicator serves as the primary measure of the Amarin Corporation plc (AMRN) business model's viability.